AR092956A1 - Sistemas de administracion y formulacion de farmacos de retencion gastrica, y metodo para su preparacion usando carbonato de calcio funcionalizado - Google Patents
Sistemas de administracion y formulacion de farmacos de retencion gastrica, y metodo para su preparacion usando carbonato de calcio funcionalizadoInfo
- Publication number
- AR092956A1 AR092956A1 ARP130103662A ARP130103662A AR092956A1 AR 092956 A1 AR092956 A1 AR 092956A1 AR P130103662 A ARP130103662 A AR P130103662A AR P130103662 A ARP130103662 A AR P130103662A AR 092956 A1 AR092956 A1 AR 092956A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- formulation
- calcium carbonate
- formulation according
- synthetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Una formulación de fármaco de retención gástrica de flotación inmediata que comprende por lo menos un mineral que comprende carbonato de calcio natural y/o sintético funcionalizado y por lo menos un ingrediente farmacéuticamente activo, y por lo menos un agente de formulación, donde dicho carbonato de calcio natural o sintético funcionalizado es un producto de la reacción de carbonato de calcio natural o sintético con dióxido de carbono y uno o más ácidos, donde el dióxido de carbono se forma in situ mediante el tratamiento ácido y/o es suministrado desde una fuente externa. Reivindicación 2: Una formulación de acuerdo con la reivindicación 1, donde la fuente de carbonato de calcio natural para la preparación del carbonato de calcio funcionalizado (FCC) se selecciona del grupo de mármol, calcita, creta, caliza o dolomita y/o sus mezclas. Reivindicación 3: Una formulación de acuerdo con la reivindicación 1, donde el carbonato de calcio sintético para la preparación del carbonato de calcio funcionalizado es carbonato de calcio precipitado (PCC) que comprende formas cristalinas mineralógicas aragoníticas, vateríticas o calcíticas, en especial, prismático, romboédrico, o escalenoédrico o sus mezclas. Reivindicación 4: Una formulación de acuerdo con cualquiera de las reivindicaciones 1 a 3, donde los ácidos se seleccionan del grupo de ácido clorhídrico, ácido sulfúrico, ácido sulfuroso, hidrosulfato, ácido fosfórico, ácido fosfórico en combinación con ácido acético, fórmico o cítrico, o sus sales ácidas, y sus mezclas, preferentemente, es ácido fosfórico. Reivindicación 7: Una formulación de acuerdo con cualquiera de las reivindicaciones 1 a 6, donde por lo menos un ingrediente farmacéuticamente activo o precursor inactivo se selecciona de aquellos de origen sintético, semisintético o natural, o sus combinaciones. Reivindicación 8: Una formulación de acuerdo con cualquiera de las reivindicaciones 1 a 7, donde por lo menos un auxiliar de formulación se selecciona de una composición y/o un compuesto formadores de película. Reivindicación 9: Una formulación de acuerdo con la reivindicación 8, donde la composición y/o el compuesto formadores de película pueden ser seleccionados de excipientes formadores de película hidrófilos o excipientes formadores de película lipófilos, o sus combinaciones. Reivindicación 10: Una formulación de acuerdo con la reivindicación 9, donde los excipientes formadores de película hidrófilos se seleccionan de polietilenglicoles solubles en agua, polietilenóxidos, polipropilenglicoles, polipropilenóxidos o sus combinaciones, donde dichos polímeros tienen un peso molecular promedio en peso de 2000 Da a 20.000.000 Da; quitosano, polímeros de ácido acrílico, polivinilpirrolidona y sus modificaciones (polivinilpirrolidonas entrecruzadas insolubles, homopolímeros de N-vinil-2-pirrolidona), gomas de celulosas modificadas, glicolatos de almidón, almidón pregelatinizado, almidón de carboximetilo sódico, hidroxipropil celulosa de baja sustitución, ésteres de alquil-, hidroxialquil-, carboxialquiI-celulosa, hidroxipropil metil celulosa ftalato, sales de carboximetilcelulosa, alginatos, resinas de intercambio iónico, gomas, quitina, arcillas, goma gelan, copolímeros de polacrilina entrecruzados, agar, gelatina, dextrinas, goma laca y sus combinaciones. Reivindicación 11: Una formulación de acuerdo con la reivindicación 9, donde los excipientes formadores de película lipófilos se seleccionan de vegetales hidrogenados, aceites de ricino, aceites minerales, ácidos grasos de ceras y sales de ácidos grasos con longitudes de cadena de carbono de C₆ a C₂₀, ramificadas, no ramificadas, insaturadas, parcialmente saturadas y sus combinaciones; estearato de magnesio y/o calcio, parafina, alcohol cetílico, cetil estearil alcohol, gliceril monoestearato, lanolina, alcoholes de lanolina, polietilenglicol éteres de n-alcanoles, derivados de aceite de ricino de polioxietileno, ésteres de ácidos grasos de sorbitano de polioxietileno, estearatos de polietileno, ésteres de sorbitano, estearil alcohol, glicerol dibehenato, estearil fumarato sódico, glicerol diestearato y sus combinaciones. Reivindicación 12: Una formulación de acuerdo con cualquiera de las reivindicaciones 1 a 11, que además comprende un ácido sólido soluble en agua. Reivindicación 13: Una formulación de acuerdo con la reivindicación 12, donde el ácido sólido soluble en agua se selecciona de ácido cítrico, ácido fumárico, ácido tartárico, o ácido málico y sus combinaciones. Reivindicación 14: Un método para la producción de una formulación de retención gástrica de flotación inmediata, que comprende las etapas de: a) la provisión de un mineral que comprende carbonato de calcio natural o sintético funcionalizado (FCC), donde dicho carbonato de calcio natural o sintético funcionalizado es un producto de la reacción de carbonato de calcio natural o sintético con dióxido de carbono y uno o más ácidos, donde el dióxido de carbono se forma in situ mediante el tratamiento ácido, y/o es suministrado desde una fuente externa; b) la provisión de por lo menos un ingrediente farmacéuticamente activo; c) la provisión de por lo menos un auxiliar de formulación; d) la mezcla de los compuestos proporcionados en las etapas a), b) y c); e) la granulación de la mezcla obtenida en la etapa d) por medio de la granulación en fundido, en seco o en húmedo, o la compactación por rodillo. Reivindicación 15: El método de la reivindicación 14, donde partes del auxiliar de formulación de la etapa c) se mezclan en primer lugar con el FCC de la etapa a) y por lo menos un ingrediente farmacéuticamente activo de la etapa b), y luego se agrega la porción restante del auxiliar de formulación a la mezcla, seguido de la etapa de granulación e). Reivindicación 34: Comprimidos, minicomprimidos, gránulos, cápsulas o miniesferas, que comprenden la formulación de retención gástrica de flotación inmediata de cualquiera de las reivindicaciones 1 a 13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12188419.1A EP2719376B1 (en) | 2012-10-12 | 2012-10-12 | Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate |
US201261713691P | 2012-10-15 | 2012-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092956A1 true AR092956A1 (es) | 2015-05-06 |
Family
ID=47022558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103662A AR092956A1 (es) | 2012-10-12 | 2013-10-09 | Sistemas de administracion y formulacion de farmacos de retencion gastrica, y metodo para su preparacion usando carbonato de calcio funcionalizado |
Country Status (27)
Country | Link |
---|---|
US (2) | US9993428B2 (es) |
EP (2) | EP2719376B1 (es) |
JP (1) | JP6189445B2 (es) |
KR (2) | KR20170103989A (es) |
CN (1) | CN104736145B (es) |
AR (1) | AR092956A1 (es) |
AU (1) | AU2013328718B2 (es) |
BR (1) | BR112015008054A2 (es) |
CA (1) | CA2885971C (es) |
CL (1) | CL2015000912A1 (es) |
DK (1) | DK2719376T3 (es) |
ES (1) | ES2536836T3 (es) |
HR (1) | HRP20150558T1 (es) |
HU (1) | HUE025008T2 (es) |
IL (1) | IL237829A0 (es) |
MX (1) | MX365522B (es) |
MY (1) | MY183859A (es) |
PL (1) | PL2719376T3 (es) |
PT (1) | PT2719376E (es) |
RS (1) | RS54024B1 (es) |
RU (1) | RU2640914C2 (es) |
SG (1) | SG11201502196TA (es) |
SI (1) | SI2719376T1 (es) |
SM (1) | SMT201500129B (es) |
TW (1) | TWI564023B (es) |
UY (1) | UY35070A (es) |
WO (1) | WO2014057026A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2949708B1 (en) | 2014-05-30 | 2018-04-04 | Omya International AG | Method for the production of granules comprising surface-reacted calcium carbonate |
AU2015265924B2 (en) | 2014-05-30 | 2017-03-30 | Omya International Ag | Method for the production of granules comprising surface-reacted calcium carbonate |
EP2957603A1 (en) | 2014-06-20 | 2015-12-23 | Omya International AG | Method for the production of granules comprising surface-reacted calcium carbonate |
EP3034070A1 (en) * | 2014-12-18 | 2016-06-22 | Omya International AG | Method for the production of a pharmaceutical delivery system |
EP3069713A1 (en) * | 2015-03-20 | 2016-09-21 | Omya International AG | Dispersible dosage form |
EP3167879A1 (en) * | 2015-11-10 | 2017-05-17 | Evonik Technochemie GmbH | Gastric retention active delivery systems |
EP3176222A1 (en) | 2015-12-01 | 2017-06-07 | Omya International AG | Method for the production of granules comprising surface-reacted calcium carbonate |
EP3260115A1 (en) * | 2016-06-21 | 2017-12-27 | Omya International AG | Method for the production of a dosage form |
EP3260114A1 (en) * | 2016-06-21 | 2017-12-27 | Omya International AG | Method for the production of a dosage form |
EP3269361A1 (en) * | 2016-07-14 | 2018-01-17 | Omya International AG | Dosage form |
EP3275946A1 (en) * | 2016-07-25 | 2018-01-31 | Omya International AG | Post treatment of surface-reacted calcium carbonate with different functional cations |
EP3275947A1 (en) | 2016-07-25 | 2018-01-31 | Omya International AG | Surface-reacted calcium carbonate with functional cations |
EP3275537A1 (en) * | 2016-07-25 | 2018-01-31 | Omya International AG | Surface-modified calcium carbonate as carrier for transition metal-based catalysts |
DK3562486T3 (da) | 2016-12-31 | 2024-06-10 | Bioxcel Therapeutics Inc | Anvendelse af sublingual dexmedetomidin til behandling af agitation |
CN106732678B (zh) * | 2017-01-20 | 2019-05-14 | 中国科学院西双版纳热带植物园 | 一种碳基磁性固体酸催化剂及其在生物柴油制备中的应用 |
US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
DK3648747T3 (da) | 2017-06-16 | 2022-11-28 | Amneal Complex Products Res Llc | Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler |
US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
CN107522216B (zh) * | 2017-07-20 | 2019-07-23 | 莆田学院 | 一种利用咪唑-4,5-二羧酸改性壳聚糖仿生合成微球球霰石的方法 |
EP3824881B1 (en) | 2018-06-18 | 2022-02-16 | Amneal Complex Products Research LLC | Extended release compositions comprising pyridostigmine |
CN112888431B (zh) | 2018-06-27 | 2022-06-03 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
US20240024288A1 (en) | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
TW202200206A (zh) | 2020-04-28 | 2022-01-01 | 瑞士商歐米亞國際公司 | 包含表面反應碳酸鈣作為賦形劑之顆粒 |
JP2023523403A (ja) | 2020-04-28 | 2023-06-05 | オムヤ インターナショナル アクチェンゲゼルシャフト | 自由流動性顆粒の製造方法 |
CN111467317B (zh) * | 2020-05-22 | 2022-03-15 | 福建海西新药创制有限公司 | 一种含有阿托伐他汀钙的药物组合物及其制备方法 |
EP3928859A1 (en) | 2020-06-23 | 2021-12-29 | Omya International AG | Surface-reacted calcium carbonate in a process for the production of a loaded microcapsule |
CN118284424A (zh) * | 2021-07-05 | 2024-07-02 | 雷鲁克斯美食有限责任公司 | 用于使用海藻酸盐、聚赖氨酸和种子防腐剂中和胃酸的方法 |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3418999A (en) | 1964-02-12 | 1968-12-31 | Donald W. Davis | Method of swallowing a pill |
JPS5512411B2 (es) | 1974-03-12 | 1980-04-02 | ||
ZA761305B (en) * | 1975-03-17 | 1977-02-23 | Hoffmann La Roche | Sustained release formulation |
JPS56101694A (en) | 1980-01-18 | 1981-08-14 | Nec Corp | Semiconductor circuit |
US4451260A (en) | 1982-03-26 | 1984-05-29 | Minnesota Mining And Manufacturing Company | Sustained release oral medicinal delivery device |
JPS6143108A (ja) | 1984-08-03 | 1986-03-01 | Nippon Shinyaku Co Ltd | 医薬品製剤及びその製造法 |
PL149493B1 (en) | 1985-04-12 | 1990-02-28 | Method of obtaining a tablet capable to buoy over surface of gastric juice | |
JPH0798742B2 (ja) * | 1986-07-03 | 1995-10-25 | ゼリア新薬工業株式会社 | 徐放性製剤組成物 |
GB8809421D0 (en) | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
EP0717988B1 (en) | 1993-08-20 | 2001-10-17 | Nippon Shinyaku Company, Limited | Gastric remaining preparation, swollen molding, and production process |
FR2762213B1 (fr) | 1997-04-18 | 1999-05-14 | Synthelabo | Composition pharmaceutique a retention gastrique |
US20010046473A1 (en) * | 1997-04-18 | 2001-11-29 | Jerome Besse | Gastric-retained pharmaceutical composition and method for its use |
FR2787802B1 (fr) | 1998-12-24 | 2001-02-02 | Pluss Stauffer Ag | Nouvelle charge ou pigment ou mineral traite pour papier, notamment pigment contenant du caco3 naturel, son procede de fabrication, compositions les contenant, et leurs applications |
FR2852600B1 (fr) | 2003-03-18 | 2005-06-10 | Nouveau pigment mineral contenant du carbonate de calcium, suspension aqueuse le contenant et ses usages | |
EP1648411A4 (en) * | 2003-07-10 | 2010-03-10 | Glaxosmithkline Llc | PHARMACEUTICAL COMPOSITIONS |
FR2881957B1 (fr) * | 2005-02-16 | 2008-08-08 | Solvay | Comprimes comprenant une substance biologiquement active et un excipient |
ES2352298T3 (es) | 2007-12-12 | 2011-02-17 | Omya Development Ag | Proceso para realizar carbonato cálcico precipitado tratado superficialmente. |
US20110268666A1 (en) * | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
EP2168572A1 (en) * | 2008-09-30 | 2010-03-31 | Omya Development Ag | New controlled release active agent carrier |
EP2376065A2 (en) * | 2008-11-14 | 2011-10-19 | Portola Pharmaceuticals, Inc. | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof |
RS52297B (en) | 2009-06-15 | 2012-12-31 | Omya Development Ag | PROCEDURE FOR OBTAINING SURFACE CARBONATE CALCIUM BY THE APPLICATION OF LOW ACID |
TWI625129B (zh) | 2011-11-10 | 2018-06-01 | 歐米亞國際公司 | 新穎的經塗布控釋活性劑載體 |
-
2012
- 2012-10-12 PT PT121884191T patent/PT2719376E/pt unknown
- 2012-10-12 RS RS20150372A patent/RS54024B1/en unknown
- 2012-10-12 DK DK12188419.1T patent/DK2719376T3/en active
- 2012-10-12 PL PL12188419T patent/PL2719376T3/pl unknown
- 2012-10-12 EP EP12188419.1A patent/EP2719376B1/en active Active
- 2012-10-12 HU HUE12188419A patent/HUE025008T2/en unknown
- 2012-10-12 SI SI201230194T patent/SI2719376T1/sl unknown
- 2012-10-12 ES ES12188419.1T patent/ES2536836T3/es active Active
-
2013
- 2013-10-01 TW TW102135465A patent/TWI564023B/zh not_active IP Right Cessation
- 2013-10-09 UY UY0001035070A patent/UY35070A/es not_active Application Discontinuation
- 2013-10-09 AR ARP130103662A patent/AR092956A1/es unknown
- 2013-10-10 BR BR112015008054A patent/BR112015008054A2/pt not_active Application Discontinuation
- 2013-10-10 MY MYPI2015701127A patent/MY183859A/en unknown
- 2013-10-10 EP EP13774198.9A patent/EP2906200A1/en not_active Withdrawn
- 2013-10-10 CA CA2885971A patent/CA2885971C/en active Active
- 2013-10-10 SG SG11201502196TA patent/SG11201502196TA/en unknown
- 2013-10-10 AU AU2013328718A patent/AU2013328718B2/en active Active
- 2013-10-10 KR KR1020177024476A patent/KR20170103989A/ko not_active Application Discontinuation
- 2013-10-10 JP JP2015536123A patent/JP6189445B2/ja active Active
- 2013-10-10 US US14/429,492 patent/US9993428B2/en active Active
- 2013-10-10 MX MX2015004084A patent/MX365522B/es active IP Right Grant
- 2013-10-10 RU RU2015117534A patent/RU2640914C2/ru active
- 2013-10-10 WO PCT/EP2013/071140 patent/WO2014057026A1/en active Application Filing
- 2013-10-10 KR KR1020157008353A patent/KR20150044030A/ko active Search and Examination
- 2013-10-10 CN CN201380052939.6A patent/CN104736145B/zh active Active
-
2015
- 2015-03-19 IL IL237829A patent/IL237829A0/en unknown
- 2015-04-10 CL CL2015000912A patent/CL2015000912A1/es unknown
- 2015-05-26 HR HRP20150558TT patent/HRP20150558T1/hr unknown
- 2015-06-03 SM SM201500129T patent/SMT201500129B/xx unknown
-
2016
- 2016-05-17 US US15/156,622 patent/US9987230B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092956A1 (es) | Sistemas de administracion y formulacion de farmacos de retencion gastrica, y metodo para su preparacion usando carbonato de calcio funcionalizado | |
ES2389358T5 (es) | Composiciones farmacéuticas de rifaximina | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
ES2371145T3 (es) | Nueva composición farmacéutica que contiene candesartán cilexetilo como sustancia cristalina lipófila. | |
EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
ES2525497T3 (es) | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico | |
MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
WO2012079092A3 (en) | Testosterone undecanoate compositions | |
MX369779B (es) | Formulacion de forma farmaceutica solida de desintegracion veloz que comprende carbonato de calcio funcionalizado y metodo para su fabricacion. | |
EA201391758A1 (ru) | Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты | |
AR069312A1 (es) | Composicion farmaceutica que comprende beta oxihidroxido de hierro en alta carga en forma adecuada para administarcion oral y que contiene al menos un hidrato de carbono y/o acido humico y su uso en el tratamiento de pacientes con hiperfosfatemia y con insuficiencia renal cronica , y procedimento pa | |
AR044142A1 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
JP2014527506A5 (es) | ||
BR112012030485A2 (pt) | composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma | |
WO2012064304A2 (en) | Combinations comprising montelukast | |
WO2009084041A3 (en) | Pharmaceutical compositions of dexibuprofen | |
AR025879A1 (es) | Granulaciones de celulosa hidrolizada de sales de farmacos | |
NZ599268A (en) | Pharmaceutical compositions of rhein or diacerein made by wet granulation process | |
HUE035112T2 (en) | A pharmaceutical composition comprising (1R, 4R) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyran [3, 4, B] indole] -4-amine and ibuprofen | |
CA2641713A1 (en) | Hydrate forms of amg706 | |
US20200306176A1 (en) | Osmotic pump controlled release formulations | |
GR20070100405A (el) | Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων | |
CN104644583A (zh) | 一种含达比加群酯的多单元微丸片剂及其制备 | |
MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. | |
PE20131107A1 (es) | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |